Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (\>18 years of age) with unresectable locally advanced or metastatic renal cell carcinoma with a clear cell component.~* Subjects must have measurable disease per RECIST 1.1 criteria.~* Subjects must not have had prior pazopanib therapy.~* Subjects must have an ECOG (Eastern Cooperative Oncology Group scoring system used to quantify general well-being and activities of daily life; scores range from 0 to 5 where 0 represents perfect health and 5 represents death.) performance status of less than or equal to 2.~* Up to 3 lines of prior VEGF (vascular endothelial growth factor) or VEGFR (vascular endothelial growth factor receptor) targeted therapy are permitted. Any prior therapy should have been completed ≥ 2 weeks prior to start of study therapy.~* Subjects may have received any number of the following therapies: cytokine therapy (e.g. high dose interleukin-2) or checkpoint inhibitor therapy (e.g. anti-PD1/PDL1, anti-CTLA4) or mTOR inhibitor therapy (e.g. everolimus, temsirolimus).~* Adequate organ and marrow function (Absolute neutrophil count \> 1000/mm3, platelets \> 100,000/mm3, aspartate aminotransferase/ alanine aminotransferase/ total bilirubin \< 1.5 X ULN (upper limit of normal). Patients with Gilbert's disease are exempt.~* Subject must be willing and able to take pazopanib with a low-fat meal every day as specified in the protocol.~* Subjects must be willing and able to come off any PPI(proton pump inhibitor)/other strong CYP3A4 inhibitors or inducers/simvastatin.~* Ability to understand and the willingness to sign a written informed consent.~* All subjects, including those who are surgically sterilized, must be willing to use an effective method of contraception.~Exclusion Criteria:~* Any concurrent health condition that in the view of the treating physician would pose excessive risk to the patient if enrolled in the study.~* Subjects with a history of hemoptysis, cerebral hemorrhage, clinically significant GI hemorrhage, myocardial infarction within the past 6 months.~* Patients at significant risk for GI (gastrointestinal) perforation or fistula.~* Pregnant or nursing mothers.~* Untreated CNS (central nervous system) metastasis. If treated CNS metastasis/es, treatment of CNS disease (surgery or radiation) must have been completed at least 30 days prior to registration. Patients could still be on steroids.~* Subjects with known history of Cirrhosis, HIV, Hepatitis B or C.~* Averaged QTc baseline in 3 ECGs (electrocardiograms) at least 5 minutes apart of ≥450 ms.~* Congestive Heart Failure (NYHA Class III/IV) or LVEF (left ventricular ejection fraction) \<50% at baseline.~* Uncontrolled hypertension (HTN) despite medical management (blood pressure (BP) ≥ 160/100.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pazopanib (Type: EXPERIMENTAL): Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal) approximately, some sample meals are described in appendix 1) every day in 14 day cycles, with a starting dose of 400 mg and adjusted for the next cycle (dose level +1:600 mg; dose level +2: 800 mg; dose level -1: 200 mg) based on toxicity assessment during or at the end of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete